Siemens Healthineers upgrades mid-term guidance

Germany-based Siemens Healthineers is now expecting revenue growth of 6-8 percent in the period 2023-2025, up from its prior 5-percent estimate. Morever, the projection for earnings per share in this period is also raised, going from 10 percent to 15 percent.

Photo: Daniel Karmann/AP/Ritzau Scanpix

Siemens Healthineers, which sells products and solutions for the prevention, diagnosing, treatment and monitoring of diseases, has upgraded its mid-term guidance, Bloomberg News reports ahead of the company's capital markets day, referring to a press release.

Following the news, Siemens Healthineers' stock price went up 3.5 percent, trading at EUR 62.52.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs